Ms. Hager joined Foundation Medicine in December 2014, bringing more than 15 years of strategic marketing, corporate and financial communications expertise in the life sciences industry to her role at Foundation Medicine. Her experience includes strategic communications in support of corporate and product brands, strategic financings and acquisitions, and regulatory actions.
Prior to joining Foundation Medicine, Ms. Hager previously served as Senior Vice President of Corporate Communications and Government Affairs for Myriant Corporation, an emerging industrial biotech company focused on the development of renewable chemicals. In this role, she successfully led all corporate, financial and advocacy communications efforts, including leading the development of new legislation, tax policy initiatives and public-private partnerships to support broad commercialization of bio-based chemicals in the United States. Before that, Ms. Hager served in a number of leadership roles with several biotech companies including Vice President of Corporate Communications and Investor Relations for Targanta (sold to The Medicines Company) and Vice President of Corporate Communications, Investor Relations and Corporate Development for Coley Pharmaceutical (sold to Pfizer). Ms. Hager's communications experience also includes leadership roles at Bayer, where she served as Senior Manager of Global Strategic Marketing Communications for the company's Diagnostics Division and later, as Senior Manager of Global Communications and Public Relations for Bayer HealthCare Worldwide. Ms. Hager also served as a Director of the Corporate and Investor Relations Practice at W2O, a global healthcare communications agency, where she championed the development and execution of strategic communications programs for publicly traded biopharma companies in the United States and Europe.
Ms. Hager holds a Bachelor of Science degree with honors in Biology and a Master's degree in Business Administration from Northeastern University.